GLP-1 receptor agonist used in FDA-approved products including Wegovy and Ozempic.
GLP-1 Weekly injection Label titration
Typical label start: 0.25 mg once weekly.
Loads a starter-dose reference only. Maintenance dosing depends on indication and prescriber direction.
Dual GIP/GLP-1 receptor agonist used in FDA-approved Mounjaro and Zepbound products.
GLP-1/GIP Weekly injection Label titration
Typical label start: 2.5 mg once weekly for 4 weeks.
Loads a starter-dose reference only. Titration and maintenance dose must come from the product label or prescriber.
Triple agonist discussed heavily online, but not an FDA-approved finished drug product.
Trending Investigational No public preset
No public calculator preset.
No dosing preset is provided because this is not an approved consumer prescription product.
Amylin analog discussed in metabolic research and combination weight-management pipelines.
Trending Investigational No public preset
No public calculator preset.
No dosing preset is provided until an approved product label is available.
GLP-1 receptor agonist used in FDA-approved Saxenda and Victoza products.
Daily injection GLP-1 Label titration
Saxenda label start: 0.6 mg daily; target 3 mg daily.
Starter preset only. Dose escalation should follow the prescribed product label.
Once-weekly GLP-1 receptor agonist used in FDA-approved Trulicity products.
Weekly injection GLP-1 Label titration
Typical adult label start: 0.75 mg once weekly.
Loads a label-start reference only. Product pens are fixed-dose and should be used as prescribed.
GLP-1 receptor agonist used in immediate-release Byetta and extended-release Bydureon products.
GLP-1 Microgram dose Diabetes label
Byetta label start: 5 mcg twice daily.
Loads a label-start reference only. Use the prescribed product instructions.
Extended-release exenatide product with once-weekly administration in approved labeling.
Weekly injection GLP-1 Fixed dose
Bydureon BCise label: 2 mg once weekly.
Reference only. Extended-release devices should be administered exactly as prescribed.
Growth hormone-releasing factor analog used in FDA-approved Egrifta SV.
Reconstitution Daily injection Vial math
Egrifta SV label: 1.4 mg daily from a 2 mg vial.
Loads the labeled Egrifta SV dose math. Use only the product-specific diluent instructions.
Bremelanotide / PT-141 FDA-label
FDA-label reference Melanocortin receptor agonist used in FDA-approved Vyleesi autoinjectors.
As-needed injection Prefilled device Label limits
Vyleesi label: 1.75 mg as needed; max 1 dose/24h and 8/month.
Reference only. This product is supplied as an autoinjector and has strict frequency limits.
Octreotide acetate FDA-label
FDA-label reference Somatostatin analog used in prescription products for acromegaly and hormone-secreting tumors.
Microgram dose Clinical use Label monitoring
Acromegaly label initial dose: 50 mcg three times daily.
Clinical reference only. Monitoring and titration are condition-specific.
Desmopressin acetate FDA-label
FDA-label reference Vasopressin analog used in prescription injection products with serious sodium-monitoring concerns.
Microgram dose Clinical use Label monitoring
Treatment-naive label start: 2 to 4 mcg daily.
Clinical reference only. Desmopressin requires prescriber-directed sodium and fluid guidance.
Parathyroid hormone analog used in FDA-approved osteoporosis injection products.
Daily injection Microgram dose Prefilled pen
Forteo label: 20 mcg once daily.
Reference only. Prefilled pen products measure the dose for the patient.
PTHrP analog used in FDA-approved Tymlos products for osteoporosis-related indications.
Daily injection Microgram dose Prefilled pen
Tymlos label: 80 mcg once daily.
Reference only. Prefilled pen products measure the dose for the patient.
Emergency and diagnostic peptide hormone products with kit-specific instructions.
Emergency kit 1 mg vial Follow label
Severe hypoglycemia label: 1 mg for adults and children >=20 kg.
No calculator preset. Emergency products should be used exactly as supplied and prescribed.
Calcitonin salmon Clinical
IU-based label Prescription calcitonin product with dosing commonly expressed in International Units.
IU dosing Clinical use Label review
Label examples include 100 International Units daily for some indications.
No preset yet because IU conversion must be compound-specific and label-driven.
Fusion-inhibitor peptide therapy for HIV with disease-specific dosing and training requirements.
Reconstitution Clinical use Specialty medication
Adult label commonly uses 90 mg twice daily.
No public preset. Specialty medications should follow pharmacy training and prescription instructions.
Prescription hormone used in highly specific obstetric and clinical settings.
Clinical setting No public preset Safety gate
No consumer calculator preset.
No preset. This is not appropriate for self-directed calculator protocols.
GnRH analog used in diagnostic and specialty endocrine contexts.
Endocrine Specialty use No public preset
No consumer calculator preset.
No preset. Dosing depends on diagnostic or specialty protocols.
Chorionic gonadotropin products are dosed in IU and vary greatly by indication.
IU dosing Fertility Clinician directed
No universal dose; label regimens are indication-specific.
No preset yet because IU dosing and clinical indication must be handled separately.
Growth hormone products are prescription medications with weight-based and indication-specific dosing.
IU/mg conversion Clinical use No public preset
No universal dose; regimens are indication-specific.
No preset. Growth hormone should stay clinician-directed with product-specific instructions.
GHRH analog commonly discussed in clinics, but public dosing should be source-reviewed before publication.
Hormone axis Review needed No public preset
No source-reviewed public preset.
No preset until current legal status, pharmacy route, and source data are reviewed.
Popular wellness compound, often offered through clinics, with nonstandard protocols.
Wellness Clinic-specific No public preset
No universal reference dose.
No preset because concentration, route, and dose vary widely by clinic and product.
Popular injectable antioxidant compound with clinic-specific concentrations and protocols.
Wellness Clinic-specific No public preset
No universal reference dose.
No preset because protocols are not standardized across products or clinics.
Popular injectable wellness compound with highly variable concentrations.
Wellness Clinic-specific No public preset
No universal reference dose.
No preset because calculator values should come from the exact vial label.
Common clinic blend category where ingredients and concentrations vary by pharmacy.
Blend Clinic-specific No public preset
No universal reference dose.
No preset because blend composition must come from the exact pharmacy label.
Very popular online recovery peptide, but FDA has identified safety concerns for compounding review.
Blocked preset Safety warning Research-only risk
No calculator preset.
No dosing preset. Do not publish protocols for compounds flagged by FDA safety-risk materials.
Thymosin beta-4 fragment frequently discussed for recovery, without an approved consumer protocol.
Blocked preset Safety warning Research-only risk
No calculator preset.
No dosing preset because FDA materials cite insufficient safety information.
GHRH analog frequently paired with secretagogues in online peptide discussions.
Blocked preset Hormone axis Research-only risk
No calculator preset.
No dosing preset because FDA materials cite adverse events and limited clinical data.
Ipamorelin Research/blocked
FDA safety-risk list Growth hormone secretagogue commonly marketed online and in clinics.
Blocked preset Hormone axis Research-only risk
No calculator preset.
No dosing preset because FDA materials cite immunogenicity and limited route-specific safety data.
Weight-management peptide fragment discussed online, without an approved public-use protocol.
Blocked preset Weight-loss trend Research-only risk
No calculator preset.
No dosing preset because FDA materials cite limited safety information and serious adverse events.
Copper peptide discussed for skin and recovery; injectable use has safety-review concerns.
Blocked preset Cosmetic trend Research-only risk
No calculator preset.
No dosing preset for injectable use because FDA materials cite limited human safety data.
Mitochondrial-derived peptide commonly discussed in longevity circles.
Blocked preset Longevity trend Research-only risk
No calculator preset.
No dosing preset because FDA materials cite lack of human exposure data.
Melanotan II Research/blocked
FDA safety-risk list Tanning peptide marketed online with serious adverse-event concerns in published case reports.
Blocked preset Cosmetic trend Safety warning
No calculator preset.
No dosing preset because FDA materials cite serious adverse events.
Thymosin alpha-1 Research/blocked
FDA safety-risk list Immune-focused peptide often discussed online, with inadequate safety information for compounding review.
Blocked preset Immune trend Research-only risk
No calculator preset.
No dosing preset because FDA materials cite inadequate safety information.
Growth hormone releasing peptide with compounding safety concerns for injectable and nasal routes.
Blocked preset Hormone axis Research-only risk
No calculator preset.
No dosing preset because FDA materials cite safety-risk concerns.
Growth hormone releasing peptide with limited safety data and metabolic concerns noted by FDA.
Blocked preset Hormone axis Research-only risk
No calculator preset.
No dosing preset because FDA materials cite safety-risk concerns.
Ibutamoren / MK-677 Research/blocked
FDA safety-risk list Oral growth hormone secretagogue often discussed in bodybuilding and longevity communities.
Blocked preset Oral compound Safety warning
No calculator preset.
No dosing preset because FDA materials cite potential congestive heart failure risk.
Heptapeptide discussed for cognition and nasal use, without approved U.S. consumer labeling.
Blocked preset Cognitive trend Research-only risk
No calculator preset.
No dosing preset because FDA materials cite limited safety information.
Peptide discussed for mood and anxiety online, without approved U.S. consumer labeling.
Blocked preset Cognitive trend Research-only risk
No calculator preset.
No dosing preset because FDA materials cite limited safety information.
Longevity peptide discussed online, without approved U.S. consumer labeling.
Blocked preset Longevity trend Research-only risk
No calculator preset.
No dosing preset because FDA materials cite insufficient safety information.
Anti-inflammatory peptide fragment discussed online, without approved U.S. consumer labeling.
Blocked preset Inflammation trend Research-only risk
No calculator preset.
No dosing preset because FDA materials cite lack of human exposure data.
Cathelicidin peptide discussed for immune support, with FDA safety-risk concerns.
Blocked preset Immune trend Research-only risk
No calculator preset.
No dosing preset because FDA materials cite limited safety data and reproductive/tumor concerns.
Mechano growth factor variant discussed for recovery and muscle, without approved U.S. labeling.
Blocked preset Recovery trend Research-only risk
No calculator preset.
No dosing preset because FDA materials cite lack of human exposure data.
Cognitive research compound discussed online, without approved U.S. consumer labeling.
Blocked preset Cognitive trend Research-only risk
No calculator preset.
No dosing preset because FDA materials cite no identified human exposure data.
Kisspeptin-10 Research/blocked
FDA safety-risk list Reproductive hormone-axis peptide with limited route-specific safety information.
Blocked preset Hormone axis Research-only risk
No calculator preset.
No dosing preset because FDA materials cite no or limited safety information.